cetuximab (MedChemExpress)
MedChemExpress is a verified supplier 
MedChemExpress manufactures this product 
95
Structured Review
MedChemExpress
cetuximab
Cetuximab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 72 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cetuximab/Cetuximab/pmc13282659-25-0-2
Average 95 stars, based on 72 article reviews
Cetuximab, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 72 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cetuximab/Cetuximab/pmc13282659-25-0-2
Average 95 stars, based on 72 article reviews
cetuximab - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Control:Article Title: MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC. Article Snippet: Efforts to block the mitogen-activated protein kinase (MAPK) pathway for colorectal cancer (CRC) therapy are challenged by frequent oncogenic mutations of its upstream genes, robust extracellular signal-regulated kinase (ERK) reactivation and difficulty in tumor-selective targeting without compromising the physiological processes of normal cells.. Deeper insight into the precise mechanism of ERK regulation could help develop potential therapeutic strategies.. Here, using integrated analyses of genomes, transcriptomes, and interactomes, we identified myotrophin (MTPN) as a crucial regulator of ERK. shRNA:Article Title: MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC. Article Snippet: Efforts to block the mitogen-activated protein kinase (MAPK) pathway for colorectal cancer (CRC) therapy are challenged by frequent oncogenic mutations of its upstream genes, robust extracellular signal-regulated kinase (ERK) reactivation and difficulty in tumor-selective targeting without compromising the physiological processes of normal cells.. Deeper insight into the precise mechanism of ERK regulation could help develop potential therapeutic strategies.. Here, using integrated analyses of genomes, transcriptomes, and interactomes, we identified myotrophin (MTPN) as a crucial regulator of ERK. Clone Assay:Article Title: MTPN drives noncanonical ERK hyperactivation in colorectal cancer and provides a promising therapeutic approach for precision medicine in CRC. Article Snippet: Efforts to block the mitogen-activated protein kinase (MAPK) pathway for colorectal cancer (CRC) therapy are challenged by frequent oncogenic mutations of its upstream genes, robust extracellular signal-regulated kinase (ERK) reactivation and difficulty in tumor-selective targeting without compromising the physiological processes of normal cells.. Deeper insight into the precise mechanism of ERK regulation could help develop potential therapeutic strategies.. Here, using integrated analyses of genomes, transcriptomes, and interactomes, we identified myotrophin (MTPN) as a crucial regulator of ERK. other:Article Title: Therapeutic targets for atherosclerotic coronary artery disease: druggable genome-wide Mendelian randomization analysis. Article Snippet: |